Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:14
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [21] Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study
    Eekeren, Louise E. van
    de Mast, Quirijn
    Meeder, Elise M. G.
    Navas, Adriana
    Groenendijk, Albert L.
    Blaauw, Marc J. T.
    Vos, Wilhelm A. J. W.
    Vadaq, Nadira
    Rutten, Joost
    Riksen, Niels P.
    van Lunzen, Jan
    Weijers, Gert
    Netea, Mihai G.
    van der Ven, Andre J. A. M.
    Tjwa, Eric T. T. L.
    Joosten, Leo A. B.
    EBIOMEDICINE, 2024, 109
  • [22] Clinical Predictors of Different Grades of Nonalcoholic Fatty Liver Disease
    Salgado Junior, Wilson
    Nonino-Borges, Carla Barbosa
    OBESITY SURGERY, 2012, 22 (02) : 248 - 252
  • [23] Nonalcoholic Fatty Liver Disease and HIV Infection
    Vallet-Pichard, Anais
    Mallet, Vincent
    Pol, Stanislas
    SEMINARS IN LIVER DISEASE, 2012, 32 (02) : 158 - 166
  • [24] Nonalcoholic fatty liver disease in children
    Alisi, Anna
    Locatelli, Mattia
    Nobili, Valerio
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2010, 13 (04) : 397 - 402
  • [25] Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Amjad, Waseem
    Shalaurova, Irina
    Garcia, Erwin
    Gruppen, Eke G.
    Dullaart, Robin P. F.
    DePaoli, Alex M.
    Jiang, Z. Gordon
    Lai, Michelle
    Connelly, Margery A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [26] Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease
    Joo, Sae Kyung
    Kim, Won
    Kim, Donghee
    Kim, Jung Ho
    Oh, Sohee
    Lee, Kook Lae
    Chang, Mee Soo
    Jung, Yong Jin
    So, Young Ho
    Lee, Myoung Seok
    Bae, Jeong Mo
    Kim, Byeong Gwan
    LIVER INTERNATIONAL, 2018, 38 (02) : 331 - 341
  • [27] The mediterranean diet, hepatic steatosis and nonalcoholic fatty liver disease
    Velasco, Nicolas
    Contreras, Alvaro
    Grassi, Bruno
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2014, 17 (05) : 453 - 457
  • [28] The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom
    Gunn, Nadege T.
    Shiffman, Mitchell L.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 109 - +
  • [29] Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis
    Kalligeros, Markos
    Vassilopoulos, Athanasios
    Shehadeh, Fadi
    Vassilopoulos, Stephanos
    Lazaridou, Ingrid
    Mylonakis, Eleftherios
    Promrat, Kittichai
    Wands, Jack R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1708 - 1722
  • [30] The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study
    Jafarov, Fuad
    Kaya, Eda
    Bakir, Alev
    Eren, Fatih
    Yilmaz, Yusuf
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (05) : 642 - 649